Physician profile
Cleopatra Thurman
NPI 1144758236
$3,202.05
in general payments reported to CMS, 2019-2025
19 companies · $17.49 in 2025
The $17.49 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $150 · 2021: $387 · 2023: $1,650 · 2024: $540 · 2025: $17.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Travel and Lodging: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.05 |
| Travel and Lodging | $1,046.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,429.16 | 2023 | |
| Biogen, INC. | $263.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $242.82 | 2019-2020 | |
| Allergan, INC. | $214.69 | 2020-2021 | |
| Ucb, INC. | $182.38 | 2021-2024 | Briviact |
| Tg Therapeutics, INC. | $132.03 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.01 | 2024 | Zeposia |
| Abbvie INC. | $112.46 | 2021-2024 | |
| Emd Serono, INC. | $100.22 | 2024 | Mavenclad |
| Amgen INC. | $92.43 | 2024-2025 | Uplizna, Aimovig |
| Neurocrine Biosciences, INC. | $87.66 | 2019 | |
| Celgene Corporation | $76.23 | 2020-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $29.53 | 2024 | Acthar |
| Lundbeck LLC | $29.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.04 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.51 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.47 | 2023 | Andexxa |
| Acorda Therapeutics, INC | $14.85 | 2024 | Inbrija |
| Amneal Pharmaceuticals LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cleopatra Thurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.